Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207454 | 0.81 | TDP1 (0.40) | EPHX2TDP1HSD11B1SMN1; SMN2LMNA | |
| SCHEMBL3014149 | 0.76 | EPHX2 (0.36) | EPHX2TDP1HSD11B1SMN1; SMN2LMNA | |
| SCHEMBL6686034 | 0.75 | L3MBTL1 (0.45) | EPHX2TDP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3008613 | 0.74 | HSD11B1 (0.36) | EPHX2TDP1HSD11B1SMN1; SMN2LMNA | |
| SCHEMBL1778693 | 0.74 | SMN1; SMN2 (0.61) | EPHX2TDP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9974906 | 0.74 | SMN1; SMN2 (0.45) | EPHX2TDP1HSD11B1SMN1; SMN2LMNA | |
| SCHEMBL14573044 | 0.71 | EPHX2 (0.53) | EPHX2TDP1SMN1; SMN2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL28651729 | 0.70 | EPHX2 (0.38) | EPHX2TDP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1420883 | 0.70 | SMN1; SMN2 (0.42) | EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL630318 | 0.70 | SMN1; SMN2 (0.42) | EPHX2TDP1HSD11B1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328826-B1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-02-26 | — | — | EP | disclosed |
| US-20180215699-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2018-08-02 | — | — | US | disclosed |
| EP-3328826-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017116-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-02 | — | — | WO | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215699-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | EPHX2 3207/4885TDP1 2050/4885HSD11B1 2993/4885 |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | EPHX2 495/4885TDP1 1332/4885HSD11B1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.